Sleep Clinical Trial
Official title:
Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition
Verified date | January 2024 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether advancing the timing of home parenteral nutrition from overnight to daytime regimens leads to improved glucose profiles and sleep quality, and other changes in plasma metabolic signatures.
Status | Completed |
Enrollment | 20 |
Est. completion date | October 24, 2022 |
Est. primary completion date | October 24, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility | Inclusion Criteria: - Adult male or non-pregnant female volunteers (age 18-79) - Short bowel syndrome diagnosis - Able and willing to give consent and comply with study procedures - Currently on routine home parenteral nutrition (at least 6 months) Exclusion Criteria: - Blind, deaf or unable to speak English - Women who are pregnant or nursing - Diabetes diagnosis or currently taking or intending to take any diabetes medication or medications influencing sugars including oral glucocorticoids, growth hormone, erythropoietin, or chemotherapeutic - Current use of sleep medication and melatonin - With skin condition that precludes wearing sensors - Within the last year, bariatric surgery or pregnancy - Within the last one month, acute infections or illnesses requiring medical attention, hospitalizations, Emergency Department visits, blood transfusions, blood loss, blood donations - Major changes in diet or physical activity level in the past 3 months - Sleep and circadian disorders (such as obstructive sleep apnea and delayed sleep phase syndrome) - Anticipated barriers or challenges to daytime and/or overnight cycled infusions |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | ASPEN Rhoads Research Foundation |
United States,
Dashti HS, Leong A, Mogensen KM, Annambhotla M, Li P, Deng H, Carey AN, Burns DL, Winkler MF, Compher C, Saxena R. Glycemic and sleep effects of daytime compared with those of overnight infusions of home parenteral nutrition in adults with short bowel syn — View Citation
Rahmoune A, Winkler MF, Saxena R, Compher C, Dashti HS. Comparison between self-reported and actigraphy-derived sleep measures in patients receiving home parenteral nutrition: Secondary analysis of observational data. Nutr Clin Pract. 2023 Oct 1. doi: 10.1002/ncp.11077. Online ahead of print. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in 24-hour average glucose from nighttime to daytime feeds | Glucose will be continuously measured using continuous glucose sensors. Blood glucose will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). | Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds). | |
Primary | Change in number of interruptions of sleep by physical movement assessed by actigraphy from nighttime to daytime feeds | Sleep will be objectively measured from actigraphy. The number of interruptions of sleep by physical movement will be calculated as 100 × the number of groups of consecutive mobile 30-s epochs/by the total number of immobile epochs. This measure will reflect sleep quality. | Actigraphy data from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds). | |
Secondary | Change in area under-the-curve of glucose from nighttime to daytime feeds | Glucose will be continuously measured using continuous glucose sensors. Area under-the-curve of blood glucose during the 12-hour feeds will be calculated using the trapezoid method and adjusted for baseline glucose values. Area under-the-curve of glucose will be averaged for each of the two 1-week feeding regimens (nighttime and daytime). | Glucose values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds) during 12-hour cycled feeds. | |
Secondary | Change in average daily duration of glucose levels above 140 mg/dl from nighttime to daytime feeds | Glucose will be continuously measured using continuous glucose sensors. Duration of glucose levels above 140 mg/dl will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). | Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds). | |
Secondary | Change in fasting insulin concentration from nighttime to daytime feeds | Serum insulin will be measured from fasting blood samples collected on day 8 and 15. | Blood draw scheduled on days 8 and 15. | |
Secondary | Change in sleep duration from nighttime to daytime feeds | Sleep duration will be objectively measured from actigraphy and sleep logs. Duration will be averaged will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). | Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds). | |
Secondary | Change in sleep midpoint from nighttime to daytime feeds | Sleep midpoint will be objectively measured from actigraphy and sleep logs. Midpoint will be averaged will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). | Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds). | |
Secondary | Change in midpoint of least-active 5h timing from nighttime to daytime feeds | Measure of sleep timing as determined from actigraphy. Timing will be averaged will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). | Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds). | |
Secondary | Change in midpoint of most-active 10h timing from nighttime to daytime feeds | Measure of sleep timing as determined from actigraphy. Timing will be averaged will be averaged during each of the two 1-week feeding regimens (nighttime and daytime). | Average values from days 1 to 7 (nighttime feeds) and days 8 to 14 (daytime feeds). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Recruiting |
NCT06079853 -
Nurse Suicide: Physiologic Sleep Health Promotion Trial
|
N/A | |
Completed |
NCT05017974 -
Research on Improving Sleep During Pregnancy
|
N/A | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT04513743 -
Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ
|
N/A | |
Completed |
NCT03251274 -
Bath Machine on Sleep Quality in Nursing Home
|
N/A | |
Completed |
NCT04102345 -
Lavender vs Zolpidem Sleep Quality During Diagnostic PSG
|
Early Phase 1 | |
Completed |
NCT03725943 -
Comparison of Dreem to Clinical PSG for Sleep Monitoring in Healthy Adults
|
N/A | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT04562181 -
Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index
|
N/A | |
Completed |
NCT05102565 -
A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers
|
N/A | |
Completed |
NCT05576844 -
Ai Youmian (Love Better Sleep) for People Living With HIV
|
N/A | |
Completed |
NCT04688099 -
Synovial Fluid Sleep Study
|
||
Recruiting |
NCT04171245 -
Prescribing Laughter for Sleep and Wellbeing in UAE University Students
|
N/A | |
Completed |
NCT03758768 -
The Effects of a Blue Monochromatic Light Intervention on Evening-type Individuals' Sleep and Circadian Rhythms
|
N/A | |
Completed |
NCT03163498 -
Evaluation of Sleep Pattern and Mood Profile in Hypertensive Patients
|
||
Completed |
NCT04093271 -
Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep
|
Phase 1 | |
Completed |
NCT03673397 -
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
|
N/A | |
Completed |
NCT04120363 -
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations
|
Phase 4 |